EA201891732A1 - Биспецифичные связывающие белки для pd-l1 и kdr - Google Patents

Биспецифичные связывающие белки для pd-l1 и kdr

Info

Publication number
EA201891732A1
EA201891732A1 EA201891732A EA201891732A EA201891732A1 EA 201891732 A1 EA201891732 A1 EA 201891732A1 EA 201891732 A EA201891732 A EA 201891732A EA 201891732 A EA201891732 A EA 201891732A EA 201891732 A1 EA201891732 A1 EA 201891732A1
Authority
EA
Eurasian Patent Office
Prior art keywords
binding proteins
bispecific binding
kdr
bispecific
human
Prior art date
Application number
EA201891732A
Other languages
English (en)
Inventor
Чжэньпин Чжу
Дан Лу
Original Assignee
Кадмон Корпорейшн, Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кадмон Корпорейшн, Ллк filed Critical Кадмон Корпорейшн, Ллк
Publication of EA201891732A1 publication Critical patent/EA201891732A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Предложены биспецифические связывающие белки, такие как биспецифические антитела, которые связываются и с PD-L1 человека, и с KDR человека. Указанные биспецифические связывающие белки эффективны для лечения заболеваний и состояний, характеризующихся иммуносупрессией и/или избыточным ангиогенезом.
EA201891732A 2016-02-02 2017-02-02 Биспецифичные связывающие белки для pd-l1 и kdr EA201891732A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662290350P 2016-02-02 2016-02-02
PCT/US2017/016230 WO2017136562A2 (en) 2016-02-02 2017-02-02 Bispecific binding proteins for pd-l1 and kdr

Publications (1)

Publication Number Publication Date
EA201891732A1 true EA201891732A1 (ru) 2019-02-28

Family

ID=59501012

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891732A EA201891732A1 (ru) 2016-02-02 2017-02-02 Биспецифичные связывающие белки для pd-l1 и kdr

Country Status (5)

Country Link
EP (1) EP3411068A4 (ru)
JP (1) JP2019506863A (ru)
CN (1) CN109310755A (ru)
EA (1) EA201891732A1 (ru)
WO (1) WO2017136562A2 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
WO2019042153A1 (zh) * 2017-09-01 2019-03-07 四川科伦博泰生物医药股份有限公司 重组双特异性抗体
EP3758735B1 (en) * 2018-02-28 2023-12-13 AP Biosciences, Inc. Bifunctional proteins combining checkpoint blockade for targeted therapy
AU2019277029C1 (en) 2018-06-01 2024-01-04 Novartis Ag Binding molecules against BCMA and uses thereof
WO2020102777A1 (en) * 2018-11-16 2020-05-22 Virtuoso Binco, Inc. Cd38 and icam1 antibodies and uses thereof
CN111196855B (zh) * 2018-11-19 2022-11-15 三生国健药业（上海）股份有限公司 抗egfr/pd-1双特异性抗体
CN111196856A (zh) * 2018-11-19 2020-05-26 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体
EP3891182A4 (en) 2018-12-03 2022-08-17 Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd RECOMBINANT PROTEIN AGAINST PD-L1 AND VEGF
CN109776683B (zh) * 2019-03-19 2020-04-07 益科思特(北京)医药科技发展有限公司 一种双特异性抗体及其制备方法与应用
CN118994397A (zh) 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
CN114286828A (zh) * 2019-06-24 2022-04-05 诺华股份有限公司 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法
US11661454B2 (en) 2019-08-09 2023-05-30 Anhui Biox Vision Biological Technology Co., Ltd. Anti-VEGF-PD1 bispecific antibody with novel structure and use thereof
CN110498857B (zh) * 2019-08-09 2022-09-09 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd1双特异性抗体
CN110563849B (zh) * 2019-08-09 2022-09-09 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd1双特异性抗体
CN110760517B (zh) * 2019-10-09 2022-04-29 天津大学 拮抗pd-1骆驼抗体类似物ap基因及蛋白和应用
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
CN113754773A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗pd1×pdl1的双特异性抗体
CN113754772A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗pdl1×kdr的双特异性抗体
CN114106190B (zh) 2020-08-31 2025-04-08 普米斯生物技术(珠海)有限公司 一种抗vegf/pd-l1双特异性抗体及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051299A2 (en) * 2003-11-19 2005-06-09 Dyax Corp. Metalloproteinase-binding proteins
AU2007282023B2 (en) * 2006-08-03 2012-09-13 Vaccinex, Inc. Anti-IL-6 monoclonal antibodies and uses thereof
US7935345B2 (en) * 2007-05-21 2011-05-03 Children's Hospital & Research Center At Oakland Monoclonal antibodies that specifically bind to and neutralize bacillus anthracis toxin, compositions, and methods of use
TWI654204B (zh) * 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
BR112013027021A2 (pt) * 2011-04-19 2016-11-29 Merrimack Pharmaceuticals Inc anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos
US9624298B2 (en) * 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
JP6312659B2 (ja) * 2012-05-31 2018-04-18 ジェネンテック， インコーポレイテッド Ｐｄ−１系結合アンタゴニスト及びｖｅｇｆアンタゴニストを用いた癌の治療方法
EP2903618B1 (en) * 2012-10-05 2022-06-01 Kadmon Corporation, LLC Rho kinase inhibitors
US20150238601A1 (en) * 2012-10-05 2015-08-27 Kadmon Corporation, Llc Treatment of ocular disorders
US20160145355A1 (en) * 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
WO2015066543A1 (en) * 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
EP3094351B9 (en) * 2014-01-15 2022-04-13 Kadmon Corporation, LLC Immunomodulatory agents

Also Published As

Publication number Publication date
CN109310755A (zh) 2019-02-05
JP2019506863A (ja) 2019-03-14
WO2017136562A3 (en) 2017-09-28
WO2017136562A2 (en) 2017-08-10
EP3411068A2 (en) 2018-12-12
EP3411068A4 (en) 2020-01-29

Similar Documents

Publication Publication Date Title
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
WO2017136562A3 (en) Bispecific binding proteins for pd-l1 and kdr
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201991720A1 (ru) Антитела к альфа-синуклеину и их применения
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
EA201990912A1 (ru) Анти-lag-3 антитела и их композиции
ZA201708265B (en) Tigit-binding agents and uses thereof
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
EA201890790A1 (ru) Связывающие pd-1 белки и способы их применения
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
EA201991546A1 (ru) Антигенсвязывающие белки против нейропилина и способы их применения
EA201790719A1 (ru) Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
EA201691541A1 (ru) Новые анти-baff антитела
EA201891331A1 (ru) Бипаратопные полипептиды - антагонисты передачи сигнала wnt в опухолевых клетках
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
JOP20190093A1 (ar) أجسام مضادة لـ il-33 واستخداماتها
EA202091315A3 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201792561A1 (ru) Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья